DIAGNOS and its Local Partner Selected Following a Competitive Bid from the Mexican Government
October 29 2019 - 9:30AM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK)
(OTCQB: DGNOF) a leader in early detection of critical health
issues through the use of its CARA platform based on Artificial
Intelligence (AI) announces today, through its local partner in
Mexico, that it has been selected after a competitive bid from the
Mexican Government for screening services among diabetic patients.
“After successful results in 2016 and 2017,
today we are very happy that the new Federal Government of Mexico
has accepted DIAGNOS’ solution to continue monitoring the diabetic
patients for the avoidance of blindness caused by diabetes. There
is no doubt that we will make an impressive 3rd cohort. The
new Government wants to do things differently and they see the
importance of having DIAGNOS’ innovative technology to assist
them”, said Axmilab, DIAGNOS’ partner in Mexico.
“As of today, DIAGNOS has delivered its CARA AI
services to more than 153,000 patients in Mexico. This has served
as a fundamental healthcare benchmark to be considered by the
health officials of the new federal government of Mexico. At
DIAGNOS we’re proud to keep assisting populations by keeping their
vision healthy and drawing awareness of such a fatal condition
caused by diabetes”, said Guillermo Moreno, Vice President at
DIAGNOS.
About AxmilabAxmilab is a Mexican company with
more than 24 years of experience by manufacturing and distributing
products in the health sector. His founder, Quim Sergio Galindo,
has successfully driven the business since its formation in 1994.
Axmilab has been a supplier of IMSS (a Mexican Governmental
organization) for the last 13 consecutive years in the diabetes
area. Since 1998, Axmilab has been working at all levels of
Government and represents major brands such as Roche, J&J,
Licon, PKL, Alifax. About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS Inc.Tel:
450-678-8882 ext. 224alarente@diagnos.ca
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Apr 2023 to Apr 2024